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Mammals obtain nitrogen via the uptake of di- and tri-
peptides in the gastrointestinal tract through the
action of PepT1 and PepT2, which are members of
the POT family of proton-coupled oligopeptide trans-
porters. PepT1 and PepT2 also play an important
role in drug transport in the human body. Recent
crystal structures of bacterial homologs revealed a
conserved peptide-binding site and mechanism of
transport. However, a key structural difference exists
between bacterial and mammalian homologs with
only the latter containing a large extracellular domain,
the function of which is currently unknown. Here, we
present the crystal structure of the extracellular
domain from both PepT1 and PepT2 that reveal two
immunoglobulin-like folds connected in tandem,
providing structural insight into mammalian pep-
tide transport. Functional and biophysical studies
demonstrate that these domains interact with the
intestinal protease trypsin, suggesting a role in clus-
tering proteolytic activity to the site of peptide trans-
port in eukaryotic cells.
INTRODUCTION
In mammals, the plasma membrane transporters PepT1
(SLC15A1) and PepT2 (SLC15A2) mediate the uptake and reten-
tion of dietary peptides (Adibi, 1997a; Matthews, 1991). PepT1
and PepT2 are proton-coupled symporters, recognizing di-
and tri-peptides on the outside of the cell and utilizing the energy
stored in the inwardly directed proton electrochemical gradientS(DmH+) to drive their uptake into the cell (Daniel and Rubio-Aliaga,
2003; Fei et al., 1994). PepT1 and PepT2 also recognize and
transport a number of important drug families, including b-lac-
tam antibiotics and anti-cancer agents (reviewed in Brandsch,
2013), and are important targets in the ongoing attempts of the
pharmaceutical industry to improve the pharmacokinetic proper-
ties of drug molecules (Brandsch, 2013; Smith et al., 2013).
PepT1 and PepT2 are members of the more widely distributed
proton-dependent oligopeptide transporter, or POT, family (TC
2.A.17), which are evolutionarily well conserved from bacteria
to man (Daniel et al., 2006). Structurally the POT family belongs
to themajor facilitator superfamily (MFS),with eachmember con-
taining 12 transmembrane (TM)-spanning a helices arranged into
two TM bundles of six that fold to resemble a V-shaped protein
that resides within the inner membrane of bacteria and plasma
membrane of eukaryotes (Figure 1) (Covitz et al., 1998; Fei
et al., 1994; Yan, 2013). The MFS fold can be further subdivided;
with each six-helix bundle being constructed from the inversion
of two three-helix repeats (Radestock and Forrest, 2011). We
recently proposed a structural framework for understanding
the transport mechanism within the POT family based on the
ability of the triple-helix repeats to work synergistically to alter-
nate the central binding site to either side of the membrane
(Fowler et al., 2015). Recent bioinformatics analyses, including
sequence-based structure alignments supported by experi-
mental structure validation, further strengthen the importance
of the triple-helix repeats. These analyses show that functionally
equivalent positionswithin thedifferentMFS transporters crystal-
lized to date superimpose in three dimensions. This observation
has led to the suggestion that evolution within theMFSmay have
arisen through intragenic duplication and shuffling of these re-
peats (Madej et al., 2013; Madej and Kaback, 2013).
Crystal structures of bacterial POT family members have
revealed a central peptide-binding site that is highly conserved
with the mammalian homologs (Doki et al., 2013; Guettoutructure 23, 1889–1899, October 6, 2015 ª2015 The Authors 1889
Figure 1. Topology of Mammalian Peptide Transporters
Topology diagram of the human plasma membrane peptide transporter PepT1. Conserved PTR2/POT family signature motifs are indicated along with predicted
N-linked glycosylation sites, three of which are in the extracellular domain. Inset: Crystal structure of the bacterial homolog PepTSt (PDB: 4D2C). The N- (light blue)
and C-terminal (wheat) domains are shown as cylinders, with the bound peptide indicating the location of the central peptide-binding site conserved between
mammalian and bacterial proteins.et al., 2014; Solcan et al., 2012). Both in vivo and in vitro assays
have demonstrated that while a wide range of peptide substrates
are transported by this family, there is conserved substrate
specificity, with both bacterial and the mammalian proteins
transporting hydrophobic peptides with approximate micro-
molar affinity and basic peptides with approximate millimolar
affinity (Newstead, 2015). Between PepT1 and PepT2 there
also exists a difference in overall substrate affinity, with PepT1
having a lower affinity for peptides and PepT2 a higher affinity
(Smith et al., 2013). Recent crystal structures of peptide-bound
complexes with a bacterial homolog of PepT1 have also sug-
gested that peptides containing extended side chains, such as
arginine and lysine, might adopt a less optimal position within
the central peptide-binding site that could explain their lower
affinity through less favorable interactions (Lyons et al., 2014).
Although the overall sequence identity between the mamma-
lian and bacterial transporters is well conserved within their
respective TM domains, epitope tagging analysis, supported
by recent structure-based sequence alignments, reveal that in
the mammalian PepT1 and PepT2 proteins there exists a signif-
icant portion of the protein that is positioned on the outside of the
cell (Covitz et al., 1998; Newstead, 2015) (Figure 1). Intriguingly,1890 Structure 23, 1889–1899, October 6, 2015 ª2015 The Authorsthese domains are completely absent not only in the bacterial
members of the POT family but also in the plant and fungal
homologs (Parker and Newstead, 2014; Sun et al., 2014) (Fig-
ure S1). The functional role of this extracellular domain (ECD) is
unknown; however, its presence would suggest the requirement
for additional functionality to assist peptide uptake in mammals.
Many eukaryotic channels and transporters have evolved to
incorporate additional structural domains that extend, constrain,
or regulate their function (Barabote et al., 2006). For example,
eukaryotic CLC proteins contain intracellular CBS (cystathionine
b-synthase) domains that regulate activity in response to nucle-
otides (Markovic and Dutzler, 2007; Meyer et al., 2007; Zifarelli
and Pusch, 2009), whereas the voltage-sensing domains of po-
tassium channels regulate channel opening following membrane
depolarization (Pongs and Schwarz, 2010). To date, however, no
equivalent domains have been described in detail for any mem-
ber of the MFS, which forms the largest and most diverse family
of secondary active transporters in biology (Reddy et al., 2012).
Here, we reveal that a previously annotated extracellular
‘‘loop’’ in early topology models of the human PepT1 and
PepT2 transporters in fact consists of two immunoglobulin-
like domains connected in tandem. In vitro binding assays
Table 1. Data Collection and Refinement Statistics for MmPepT1ECD and RnPepT2ECD
MmPepT1ECD MmPepT1ECD-Hga RnPepT2ECD-Sea RnPepT2ECD
Space group P212121 P212121 P3221 P412121
Cell dimensions
a, b, c (A˚) 53.48, 70.33, 111.22 53.55, 70.37, 111.16 95.75, 95.75, 165.93 43.1, 43.1, 220.1
a, b, g () 90, 90, 90 90, 90, 90 90, 90, 120 90, 90, 90
Wavelength (l) 0.968 1.006 0.979 0.976
Resolution (A˚) 43–2.10 (2.19–2.10) 70–2.85 (3.05–2.85) 58–2.81 (2.96–2.81) 43–2.06 (2.12–2.06)
Rmerge 5.0 (79.8) 17.2 (75.6) 15.4 (109) 6.6 (67.1)
MnI/sI 16.4 (2.7) 15.1 (4.1) 12.7 (2.3) 11.5 (2.3)
CC1/2
b 99.9 (48.0) 99.7 (91.0) 99.9 (69.7) 99.8 (63.9)
Completeness (%) 99.5 (99.0) 99.4 (99.7) 99.9 (99.9) 99.3 (99.5)
Redundancy 4.8 (4.8) 14.0 (14.5) 9.9 (10) 4.1 (4.3)
Rcullis (%) 69.2 45.1
Phasing powerc 1.492 2.468
Resolution (A˚) 43.6–2.10 58.6–2.81 40.1–2.06
No. of reflections 24, 975 22, 048 13, 635
Rwork/Rfree 19.7/23.8 19.7/24.5 19.9/24.0
Ramachandran favored 96.6 92.5 96.3
Ramachandran outliers 0.53 0.17 0
Rmsd
Bond lengths (A˚) 0.010 0.010 0.010
Bond angles () 1.18 1.31 1.25
aFor details on derivatization, see Experimental Procedures.
bMn(I) half-set correlation as reported by Aimless.
cPhasing power = rms(jFHj/((FH + FP)  (FPH))).demonstrate that the ECDs interact with the intestinal protease
trypsin, potentially answering an interesting observation made
in the late 1960s of a specific and tight interaction of trypsin
with human intestinal mucosa (Goldberg et al., 1968, 1969a,
1969b). More surprising was the observation that these domains
can be removed with no appreciable loss of transport function.
These results provide the first structural and biochemical in-
sights into the mammalian SLC15 family, and demonstrate
modularity within theMFS that could have important implications
for interpreting the function of these proteins in eukaryotic cells.
RESULTS
Crystal Structures of the Extracellular Domain of PepT1
and PepT2
Using the crystal structures from the bacterial POT family pro-
teins PepTSo (Newstead et al., 2011) and PepTSt (Solcan et al.,
2012) that share 31% and 21% identity, respectively, with their
mammalian homologs, we identified the probable location of
the ECD in the PepT1 transporters (Figure S1). We subsequently
identified the ECD from Mus musculus, consisting of residues
391–580, as being stable and amenable to structural and bio-
physical analysis (Figure S2). This domain was crystallized and
its structure determined using the single anomalous dispersion
(SAD) method of phasing using mercury-derivatized protein.
The structure was refined to a resolution of 2.1 A˚ with final Rwork
and Rfree of 19.7% and 23.8%, respectively (Table 1). Following
extensive screening, crystals from Rattus norvegicus PepT2,Sresidues 410–601, were also obtained (Figure S2). The phases
were calculated from seleno-L-methionine incorporated protein
using the SAD method in space group P3221 (Table 1). A higher-
resolution structure in space group P41212 was obtained using
the P3221 crystals as seeds with a single monomer in the asym-
metric unit. The final structure refined to a resolution of 2.06 A˚
with final Rwork and Rfree of 19.9% and 24.0%, respectively.
The crystallographic asymmetric unit of the PepT1ECD crystal
contained twomonomers that formedahead-to-tail dimer, related
by a two-fold non-crystallographic symmetry axis (Figure 2A),
whereas the PepT2ECD construct was crystallized in amonomeric
state (Figure 2B). The overall structure of both ECDs consists
of two compact b-sandwich immunoglobulin-like folds each
comprising two four-stranded b sheets. The b sandwiches are
composedof strands in theorder4-1-7-8and3-2-5-6,witha short
connecting loop between the end of strand b-8 on lobe one and
b-9 on lobe two. Despite having only 22% sequence identity the
two structures adopt the same overall structure, superimposing
with a root-mean-square deviation (rmsd) of 1.83 A˚. Analytical ul-
tracentrifugation on the purified ECDs show that both PepT1ECD
and PepT2ECD are monomers in solution (Figure 2C). This led us
to suspect that the head-to-tail dimer observed in the asymmetric
unitwas the result of crystallizationand that thephysiological state
of the ECD in PepT1 is monomeric, as shown for the PepT2ECD.
Thebilobalarchitectureof theECDssuggested that the two immu-
noglobulin-like domains have the potential to be highly dynamic,
which could represent an important structural and functional
difference between PepT1 and pepT2.tructure 23, 1889–1899, October 6, 2015 ª2015 The Authors 1891
AC
B Figure 2. Crystal Structure of the Extracel-
lular Domain from PepT1 and PepT2
(A) The asymmetric unit of MmPepT1ECD con-
taining two monomers related by a two-fold non-
crystallographic symmetry axis (black oval). One
monomer is rainbow colored from the N termi-
nus to the C terminus; the second is shown in
gray with the secondary structure labeled from b1
to b16.
(B) Structure of the RnPepT2ECD colored from
the N (blue) to the C terminus (red) and with
the secondary structure components labeled as
for (A).
(C) The s020,W values of MmPepT1
ECD and
RnPepT2ECD from the AUC analysis are 2.16 and
2.22, respectively, consistent with both proteins
migrating as a 20-kDa monomer in solution. Inset:
the Lamm equation fit profiles for MmPepT1ECD
and RnPepT2ECD.Salt Bridge Interactions Stabilize the Interface between
the Immunoglobulin-like Domains in PepT1
The crystal structures revealed that in the PepT1ECD there exist
two conserved salt bridge interactions stabilizing the interface
between lobe 1 and lobe 2, mediated by Asp574-Lys398 and
Asp476-Arg490, whereas in PepT2ECD only one equivalent salt
bridge interaction is present, between Asp505 and Arg538 (Fig-
ures 3A and 3B). To investigate the nature of these interactions,
we inserted a 3C protease site into the linker connecting lobe 1
and lobe 2 in PepT1ECD (Figure 3C). Following cleavage by the
protease 3C of the purified protein, we observed that the two
lobes of PepT1ECD remain associated down a size-exclusion
chromatography column. Repeating this experiment with the As-
p574Ala variant, however, resulted in the two lobes migrating
independently, thus confirming the importance of the salt bridge
in holding the two immunoglobulin-like domains together in the
compact arrangement shown in Figure 3A.
The same experiment, however, could not be conducted with
PepT2ECD as the lobes proved too unstable after cleavage with
3C protease. Therefore, to understand the behavior of PepT2ECD
in solution we used small-angle X-ray scattering (SAXS), a
method that allows the overall shape of a macromolecule to be
modeled at low resolution. Guinier analysis of the scattering
data in PRIMUS (Petoukhov et al., 2007) shows that PepT2ECD
has a larger radius of gyration (Rg) compared with PepT1
ECD,
23.1 versus 18.4 A˚ (Table 2), which suggests an increase in parti-
cle size. A shift to larger scattering distances can also be seen in
the P(r) distribution and dimensionlessVc Krakty plot (Rambo and
Tainer, 2011) (Figures S3A and S3B), indicating amore elongated
structure for PepT2ECD. Consistent with this analysis, 3D enve-
lopes of the ECD generated usingDAMMIF (Franke and Svergun,
2009) show that PepT1ECD forms a compact shape 48 A˚ in
length whereas PepT2ECD is more elongated, approximately
61 A˚ in length (Figures 3D and S3C). The larger envelope of Pep-
T2ECD indicates that the two immunoglobulin-like domains are
structurallymoredynamic than thePepT1ECD,which is consistent
with the loss of the second salt bridge and also the location of
Asp505 on the unstructured loop connecting lobes 1 and 2.1892 Structure 23, 1889–1899, October 6, 2015 ª2015 The AuthorsPepT1 and PepT2 Contain a Functionally Independent
Extracellular Domain
To date there have been no studies on the role of the ECDs in
either of the mammalian peptide transporters. This is largely
due to the ambiguity in identifying where this domain was
located with respect to the TM helices. The crystal structure of
the ECDs from both PepT1 and PepT2 now allow for structure-
based homology models of the full-length human transporters
to be built (Figure 4A). Molecular dynamics of the models in a
palmitoyloleoyl phosphatidylglycerol membrane bilayer suggest
that the domains are likely to adopt a vertical orientation sitting to
one side of the transporter (Figure S4).
PepT1 and PepT2 are the first MFS transporters to date that
have been shown to contain a folded structural domain inserted
within the ‘‘core’’ MFS fold (Yan, 2013). This raises the important
question of whether the ECDs play any role in transport or
determine functional differences between PepT1 and PepT2.
To investigate this question, we used the homology models to
generate a number of different combinations of chimeric and
mutant human PepT1 and PepT2 transporters that had their
ECD domains removed (PepT1DECD, PepT2DECD) or swapped
(PepT1ECD2, PepT2ECD1). The resulting constructs were ex-
pressed in Xenopus oocytes and their relative levels of expres-
sion examined (Figure S5). We observed that PepT1 was very
sensitive to modification at or within the ECD, with only the
wild-type (WT) showing stable levels of expression. In contrast,
we observed high levels of expression for all of the PepT2
constructs, allowing us to investigate the role of this ECD. Pep-
tide transporters are electrogenic carriers able to concentrate
peptides inside the cell using the energy stored in the DmH+
(Fei et al., 1994). We therefore examined their transport prop-
erties using two-electrode voltage-clamp (TEVC) recordings
in the Xenopus laevis oocytes. This technique measures the in-
ward movement of H+ as a function of external peptide concen-
tration. KM values for transport of the non-hydrolyzable peptide
glycyl-sarcosine (Gly-Sar) were determined for both WT PepT1
and PepT2. The calculated KM values confirm the previously
noted difference in peptide transport of 0.78 ± 0.09 mM and
Figure 3. Salt Bridges Stabilize the Interface between the Two
Immunoglobulin-like Domains in PepT1ECD and PepT2ECD
(A) Structure of PepT1ECD illustrating the two salt bridges, K398 and D574 and
R490 and D476, that form an interaction between the lobes.
(B) Comparative view in RnPepT2ECD, where a single salt bridge is observed
between Asp505 and Arg518.
(C) Size-exclusion chromatography traces from the MmPepT1ECD-3CX
experiment. The cleaved MmPepT1ECD-3CX constructs elute at the same
volume as wild-type, showing that the lobes still interact in solution even after
the two lobes are separated. The cleaved MmPepT1ECD-3CX-D574A
construct, however, elutes in a larger volume consistent with disruption of the
interaction.
(D) DAMMIN envelopes of MmPepT1ECD (dark purple) and RnPepT2ECD (light
purple) calculated from the SAXS data, which show lengths of 48 and 61 A˚,
respectively, and illustrate the more dynamic behavior of PepT2ECD. For scale,
a black and white outline of A is overlaid on the MmPepT1ECD envelope.0.32 ± 0.02 mM for PepT1 and PepT2, respectively (Figure 4B).
However, swapping the ECD region from PepT1 to PepT2
(PepT2ECD1) or even deleting it entirely from PepT2 (PepT2DECD)
resulted in no detectable change in the KM for uptake of
the Gly-Sar peptide, which remained 0.3 mM. Additionally,
removal of the salt bridge that stabilizes the interface between
lobes 1 and 2 of PepT1 (PepT1D573A) made no observable differ-
ence to the KM of Gly-Sar transport (Figure 4C). We also tested
whether these constructs interacted differently with the antibi-
otic cefaclor, a known substrate of PepT1 and PepT2 (Bretsch-
neider et al., 1999; Luckner and Brandsch, 2005). We found
that the Ki of drug uptake in cis-inhibition experiments wasSalso unchanged for all the PepT2 constructs, with a Ki of
0.22 mM, compared with 0.9 mM for WT PepT1 (Figure 4D).
This similarity was also shown with a different non-hydrolyzable
peptide, lysyl-lysine. These results indicate that the ECD is
a structurally independent unit that has no obvious role in
substrate specificity or intrinsic peptide transport function, in
PepT2 at least. The immunoglobulin-like structure of the ECDs,
however, strongly suggested a possible role in binding an
external component that might be present in the intestinal lumen.
Therefore, to further investigate the function of the ECDs we un-
dertook a series of binding studies to investigate this possibility.
The Extracellular Domain Interacts with the Intestinal
Protease Trypsin
Given the expression of both PepT1 and, to a lesser extent,
PepT2 in the intestinal brush border membrane, we thought it
possible that the interaction partners may be intestinal hor-
mones, including cholecystokinin (CCK8) and thyroid hormone,
which has been reported to decrease the surface expression
of PepT1 in Caco-2 cells (Ashida et al., 2002). Another possibility
was an interaction with the intestinal proteases that create
the di- and tri-peptides that are subsequently recognized by
PepT1 and PepT2 for transport into the cell. We therefore
screened a panel of potential interaction candidates using
surface plasmon resonance (SPR). From this panel of potential
ligands we observed binding only for the intestinal protease
trypsin with both mouse PepT1ECD (KD 80 ± 0.8 mM) and rat
PepT2ECD (KD 165 ± 0.5 mM) (Figures 5A and 5B). However, we
observed no significant interaction between PepT1ECD and
chymotrypsin or pepsin. It is possible that one function of the
ECDs could be to interact with and accumulate peptides in the
vicinity of the transporter, although this would be unlikely given
the TEVC data. However, to test this we used microscale ther-
mophoresis (MST), which can measure the interaction with small
ligands with transporters in solution (Parker and Newstead,
2014). We did not observe an interaction with the peptide
Gly-Sar, but this technique did confirm our previous SPR data
showing a specific interaction with trypsin (Figure 5A). The KD
calculated using this technique, however, was tighter than that
observed using SPR, being 8 ± 0.7 mM for PepT1ECD and 6 ±
0.5 mM for PepT2ECD. We interpret this discrepancy with the
SPR values as being due to the freedom of interaction of a mea-
surement in solution versus immobilization on a chip surface. To
examine the nature of the interaction between trypsin and the
ECDs, we repeated the MST binding assay with an increased
salt concentration of 0.5 M. This resulted in abolition of the inter-
action, suggesting that the interaction between trypsin and the
ECD is mediated through an electrostatic interface.
Trypsin Recognition Is Localized to a Conserved
Di-aspartate Motif on the Extracellular Domain
To identify possible binding sites on the PepT1ECD and PepT2ECD
molecules, we mapped the sequence conservation for six
different mammalian homologs (Figure S1) onto the crystal struc-
tures. We identified two highly conserved charged residues,
Asp550 and Glu573 in PepT1ECD and Asp576 and Glu599 in
PepT2ECD, located on one face of the ECD structure (Figures
5D and 5E). Both of these residues are found in two conserved
sequence motifs at the start of strand b15 and at the end oftructure 23, 1889–1899, October 6, 2015 ª2015 The Authors 1893
Table 2. SAXS Data Statistics forMmPepT1ECD and RnPepT2ECD
Rg (A˚) I(0)/Conc (mg ml
1) Vp (nm
3) Dmax (A˚) Vc (A˚
2) Mass (kDa)
MmPepT1ECD 18.4 ± 1.7 8.6 ± 0.0 33.4 64.3 197 17.1
RnPepT2ECD 23.0 ± 2.8 14.9 ± 0.0 45.4 73.1 238 20.1
The Rg, I(0)/Conc, Vp, and Dmax were calculated in PRIMUS. The Vc and particle mass were calculated in ScA˚tter, and show that RnPepT2
ECD has a
larger radius of gyration (Rg) in solution, indicating a more flexible arrangement for the two lobe domains.strand b16 in lobe 2 of the mammalian proteins (Figure S6).
Removal of these charges abolished the interaction with trypsin
(Figures 5D and 5E, insets), further supporting the hypothesis
that the function of the ECD is to recruit trypsin to the site of
the peptide transport on the plasma membrane. The other face
of the ECD, however, does not contain any conserved charged
residues, suggesting that this face in unlikely to be important in
an electrostatic interaction. Indeed, mutation of several surface
residues in mouse PepT1ECD resulted in no substantial impact
on the KD of trypsin binding compared with WT protein (Fig-
ure S7). The involvement of only two conserved residues in the
trypsin interaction may also explain the fast binding kinetics
observed in the SPR sensorgrams (Figures 5A and 5B, insets),
which suggest that the interaction with trypsin is highly dynamic
and likely transient, rather than forming a long-lived complex in
the intestinal lumen.
DISCUSSION
The Modular Architecture of PepT1 and PepT2
Mammalian peptide transport is a physiologically important
route to both assimilate dietary nitrogen in the form of small
di- and tri-peptides from ingested protein and retain peptides
in the body by selective reabsorption in the kidneys (Adibi,
1997b; Matthews, 1975; Matthews, 1991). Although originally
identified in 1994, the 3D structures of PepT1 and PepT2 have
remained elusive, and to date no crystal structures are available.
However, recent crystal structures of several closely related
bacterial homologs provide suitable templates to model the
TM domain of the mammalian proteins (Newstead, 2015; Terada
and Inui, 2012). Nevertheless, the identity of the ECD, originally
identified from hydropathy analysis and epitope insertion studies
(Covitz et al., 1998), has remained elusive. Our functional and
structural analysis shows that the ECD is a fully independent
module that has been incorporated by the mammalian members
of the POT family to function in protein-protein interactions on
the outside of the cell. Additional structural domains are found
in many families of membrane transporters (Barabote et al.,
2006). However, the locations of the ECDs within the PepT1
and PepT2 structures are particularly intriguing, in that they are
insertedwithin the canonical 12-TM helix MFS fold. This is highly
unusual; most additional domains in transporters are appended
to either the N- or C-terminal end of the polypeptide chain (Mar-
kovic and Dutzler, 2007; Meyer et al., 2007; Warmuth et al.,
2009). To our knowledge, this study reports the first structure
of an additional domain inserted within the core architecture of
a transporter. Interestingly the insertion site within PepT1 and
PepT2 is the connection between TM9 and TM10, which repre-
sents the junction between the two triple-helix repeats that
make up the C-terminal bundle within the MFS fold (Radestock1894 Structure 23, 1889–1899, October 6, 2015 ª2015 The Authorsand Forrest, 2011). We recently suggested that these repeats
operate in a scissor-like motion that control access to the central
peptide-binding site during transport (Fowler et al., 2015). The
insertion of the two immunoglobulin-like domains of the ECD,
with minimal impact on the ability of PepT1 and PepT2 to func-
tion as proton-coupled peptide symporters, would appear to
support our hypothesis that the two repeats operate in a coordi-
nated but structurally independent manner.
However unusual it may be to observe the ECD inserted within
the canonical MFS fold, our finding that both the PepT1ECD and
PepT2ECD interact with trypsin presents a logical role for these
domains in mammalian peptide import. It is interesting to note
that as far back as 1968 both trypsin and chymotrypsin were
observed to interact with and bind to themucosa of human small
intestine (Goldberg et al., 1968, 1969a, 1969b). The assay condi-
tions used here to investigate the binding between the ECD and
trypsin closely resemble the pH and ionic strength found in the
small intestine (150 mM NaCl and pH 6.5) (Fallingborg,
1999; Fordtran et al., 1968), suggesting that the KD values re-
ported are likely to be in the physiological range. Furthermore,
the KD values reported in this study (mM range) are also consis-
tent with the estimated concentration of trypsin in the small intes-
tine, which was reported to be 7 mM (Goldberg et al., 1969a).
Taken together, these observations support the presence of a
physiological interaction between the ECD of PepT1 and
PepT2 and trypsin in the human body. Our data show that a
conserved di-acidic motif on both PepT1ECD and PepT2ECD pre-
sents the most likely interaction site with trypsin. However, the
fast binding kinetics show that the interaction is highly dynamic
and likely to be transient in nature. We have combined all of
the information presented to generate a working hypothesis for
how trypsin might interact with PepT1 and PepT2 at the plasma
membrane (Figure 6). Our data place trypsin on the opposite side
of the ECD to the peptide translocation pathway (Newstead,
2015). In this configuration the binding of trypsin would not
obstruct subsequent peptide transport, as the protease would
be on the opposite side of the transporter from the peptide-bind-
ing site.
Why would PepT1 and PepT2 have evolved to localize trypsin
rather than other proteases, such as chymotrypsin? PepT1 and
PepT2 play an important physiological role in absorbing small
peptides arising from digestion of dietary proteins in the small
intestine, as well as in reabsorbing filtered peptides generated
from luminal peptidases in the kidney (Adibi, 1997a, 1997b).
There is clearly an advantage in tethering a protease to the
site of peptide uptake on the plasma membrane, in that the
peptides will be locally concentrated at the site needed for
their recognition and transport. The localization of trypsin, which
recognizes and cleaves the peptide chain at arginine and
lysine residues, would therefore increase the concentration of
Figure 4. PepT1 and PepT2 are Modular Proteins with Functionally Distinct Domains
(A) Homology model of the human PepT1 transporter generated using the crystal structure ofMmPepT1ECD (colored blue to red as in Figure 1B) and the recently
determined bacterial homolog PepTSo representing the transmembrane portion of the transporter (shown in gray). The peptide-binding site is highlighted
(magenta).
(B) Kinetic analysis of Gly-Sar uptake in human PepT1 and PepT2 using the TEVC method.
(C) Kinetic analysis of Gly-Sar uptake in the PepT2DECD, PepT2T1ECD, and PepT1D573A constructs.
(D) Ki values for the different constructs for lysyl-lysine and cefaclor are shown, indicating no effect of removing the ECD on peptide or drug uptake in PepT2.peptides containing these side chains on the outside of the cell
directly above the peptide-binding site, and would be expected
to improve the efficiency of their uptake through the transporter
domain. Indeed, clinical studies of peptide transport in the
human body have indicated that the transport of arginine-con-
taining peptides is less efficient (Steinhardt and Adibi, 1986),
consistent with our findings from the bacterial homolog of
PepTSt (Solcan et al., 2012), suggesting that the localization of
trypsin is an adaption to increase the concentration of peptides
containing arginine and lysine, and therefore improve the trans-
port of these peptides into the cell. We hasten to acknowledge,
however, that our data do not unambiguously demonstrate a
physiological requirement for trypsin in peptide transport and
that our hypothesis will require further in vivo study for it to be
supported or refuted.
To our knowledge, this study represents the first structural
insight into MFS transporters that exist as multi-domain pro-
teins. Interestingly, a similarly sized ECD is also observed in
the SLC22 family of MFS transporters, again inserted between
TM9 and TM10 (Kalliokoski and Niemi, 2009), suggesting that
other eukaryotic MFS transporters have adopted similar mecha-Snisms to extend their functionality in the cell. The present study
and homology models of the human PepT1 and PepT2 trans-
porters therefore not only establish a framework for understand-
ing mammalian peptide uptake, but also show how members
of the MFS have evolved to incorporate additional structural
domains that expand, augment, or constrain their function in
eukaryotic cells.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of the Extracellular Domains
from PepT1 and PepT2
PepT1ECD from M. musculus (residues 391–580, UniProtKB: Q9JIP7) was
cloned into an N-terminal maltose-binding protein (MBP) fusion expression
vector, pOPINM (Berrow et al., 2007). PepT2ECD from R. norvegicus (residues
410–601, UniProtKB: Q63424) was cloned into a different MBP fusion expres-
sion vector, pLou3, a derivative of pMAL-c5 vector with a tobacco etch virus
protease site, to remove the MBP and an N-terminal histidine tag. Recombi-
nant protein was produced in Escherichia coli strain BL21-DE3. Isopropyl
b-D-1-thiogalactopyranoside was used to induce expression of the recombi-
nant genes; cells were harvested following overnight induction at 25C. WT
and mutant proteins were purified to homogeneity using standard proto-
cols for Ni-immobilized metal affinity chromatography- and amylose-basedtructure 23, 1889–1899, October 6, 2015 ª2015 The Authors 1895
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Figure 5. Trypsin Interacts with a Di-acidic Motif on the Extracellular Domain of PepT1 and PepT2
(A) SPR analysis of theMmPepT1ECD interaction with trypsin. Inset: SPR sensorgram used to determine the binding constant. RU, response units. Error bars show
the SEM (n = 3).
(B) The binding experiment in (A) was repeated with the RnPepT2ECD protein.
(C) MST binding analysis reveals no interaction with the Gly-Sar peptide and abolition of trypsin interaction in the presence of high salt.
(D and E) Surface representation of (D) MmPepT1ECD and (E) RnPepT2ECD with the sequence conservation from cow, dog, chicken, human, mouse, and rat
species mapped from blue to red. A highly conserved patch (indicated by the white dashed ellipse) was identified. Insets: MST binding analysis reveals an
important role for D550 and E573 in MmPepT1ECD, and D576 and E599 in RnPepT2ECD, in mediating the electrostatic interaction with trypsin.purification of the fusion proteins. Seleno-L-methionine-incorporated
PepT2ECD was produced using an auto-inducing medium, PASM-5052
(Studier, 2005).
Crystallization and Structure Determination
PepT1ECD was crystallized in 20% polyethylene glycol (PEG) 6000, 0.1 M 2-
(N-morpholino)ethanesulfonic acid (MES) (pH 6.0), 0.2 M ammonium chloride,
at 10 mg ml1 and 4C using sitting drop-vapor diffusion plates. All crystals
were cryo-protected in mother liquor with 25% glycerol and cryo-cooled in
liquid nitrogen for data collection. Diffraction data were collected on beam-
lines I24, I03, and I04 at Diamond Light Source, Harwell, UK. Initial data pro-
cessing was carried out using the Xia2 pipeline (Winter et al., 2013) to XDS
(Kabsch, 2010). Initial phases for PepT1ECD were calculated using SAD with
a single mercury-derivatized crystal. The space group was determined to be
P212121. Threemercury siteswere initially located using SHELXC/D (Sheldrick,
2010), with their positions further refined and initial phases calculated using
SHARP with solvent flattening in SOLOMON (Abrahams and Leslie, 1996).
The complete primary structure was assigned in Coot and refined using
BUSTER (Blanc et al., 2004) to a final resolution of 2.10 A˚ and Rwork/Rfree of
19.7/23.8 (Table 1).
RnPepT2ECD was crystallized in 0.2 M (NH4)3 citrate (pH 5.8) and 21% PEG
3350, 10 mg ml1 at 20C. Initial phases were calculated using Se-SAD data
using autoSOL from the PHENIX crystallography suite (Adams et al., 2010).
A starting model was built using PHENIX Auto-Build showing three molecules
in the asymmetric unit in space group P3221. The complete structure of the
three molecules was built in Coot based on this initial map. Refinement of
the structure was carried out in BUSTER to a final resolution of 2.81 A˚ with1896 Structure 23, 1889–1899, October 6, 2015 ª2015 The Authorsan Rwork/Rfree of 19.7/24.5. To improve the resolution of the PepT2
ECD struc-
ture, we re-screened the original sparse matrix crystal screens using a seed
stock generated from the P3221 crystals. Crystals grew in 0.2 M CsCl2 and
15% PEG 3350. A dataset was collected on beamline IO3 at Diamond Light
Source and processed using XDS to a resolution of 2.06 A˚ in a new space
group, P41212. The phases for this new structure were calculated bymolecular
replacement of the monomeric PepT2ECD structure in Phaser (McCoy et al.,
2007). The model was refined in BUSTER to a final Rwork/Rfree of 19.9/24.0.
Homology Models of Human PepT1 and PepT2
Homology models of the human PepT1 (UniProt: P46059) and PepT2 (UniProt:
Q16348) transporters were built consisting of the crystal structure of a bacte-
rial peptide transporter, PepTSo (Newstead et al., 2011) (PDB: 2XUT) as the
template for the transmembrane region, and the crystal structures of the
ECD regions inserted within the extracellular loop connecting TMH9 and
TMH10. The two extra helices, HA and HB (residues 226–285), which are
only present in a subset of the prokaryotic POT family transporters, were
removed prior to the sequence alignment. Initial alignment was generated
using Probcons (Do et al., 2005), and this was manually refined in Jalview
(Waterhouse et al., 2009) to correctly align the functionally important residues
identified previously through functional studies on the eukaryotic andmamma-
lian homologs.
Expression and Functional Characterization of Human PepT1 and
PepT2 in Xenopus Oocytes
Open reading frames for the human PepT1 and PepT2 proteins were cloned
into the pBF Xenopus oocyte expression vector, which adds the 50 and 30
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Figure 6. A Model for the Interaction between Trypsin and the
Mammalian Peptide Transporters
During protein digestion in the small intestine, trypsin transiently docks onto
the conserved di-acidic motif on the trypsin-binding domain, localizing the
protease to the main site of peptide import on the brush border membrane.
Localization would create an increase in the local concentration of arginine-
and lysine-containing peptides (shown here as blue circles), which would be
expected to increase the efficiency of their uptake into the cell.UTRs of the Xenopus b-globin gene. ECD deletions and chimeras were gener-
ated using extension overlap PCR. A C-terminal FLAG tag epitope was engi-
neered at the C terminus of these genes to aid detection and quantitation of
expression by western blot. mRNA for injection was prepared by in vitro tran-
scription using the AmpliCap SP6 High Yield Message Maker kit (Cellscript).
Xenopus oocytes were injected with 50 ng of mRNA and incubated at 17C
for 3–4 days before recording. For TEVC recordings, microelectrodes were
filled with 3 M KCl and had tip resistances of 5 MU. Oocytes were voltage-
clamped at 50 mV, and a voltage step protocol consisting of 300-ms long
pulses from 160 to +60 mV in 10-mV increments was used to test oocyte
stability and record currents. ND96 solution was used as the bath solution
(95.4 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 5 mM HEPES [pH 7.5] with
NaOH). Test solutions consisted Gly-Sar at desired concentrations in ND96
solution. Transport-associated currents were estimated by subtracting cur-
rents recorded on ND96 solution only from those in the presence of substrate
for each experiment. The currents at each Gly-Sar concentration were normal-
ized to the maximal current (taken as current observedwith 10mMGly-Sar) for
each oocyte and the current at120mV at each Gly-Sar concentration used in
non-linear regression analysis. Data were analyzed using Clampfit 10.4.0.36
(Axon Instruments) and non-linear regression analysis was performed on
data from single oocytes using GraphPad Prism (version 6.04 for Mac, Graph-
Pad Software). Acquired data were fitted to the Michaelis-Menten equation I =
(Imax[Gly-Sar])/(KM + [Gly-Sar]), where current was used in the place of velocity
to calculate an apparent KM for data from each oocyte. Average KM was then
taken as the mean of the KM values from individual oocytes expressing the
specific construct and displayed as mean ± SEM. Background currents
were measured in uninjected oocytes 4 days after incubation. Inhibition exper-
iments with the b-lactam antibiotic cefaclor and the dipeptide lysyl-lysine
determined cis-inhibition of [3H]-D-Phe-L-Gln uptake by increasing concentra-
tions of cefaclor or lysyl-lysine, using the method of Pieri et al. (2009). 10 ng of
mRNA was injected into each oocyte.
Small-Angle X-Ray Scattering
SAXSdatawere collected at the P12 beamline (PETRA III, Hamburg) at awave-
length of 1.24 A˚. Scattered images were collected on a PILATUS 2M detector
(Dectris) at 297 K. Twenty images were taken while the sample was continually
passed through a quartz capillary. Samples and buffers were prepared using
the same protocol used for the area under the curve (AUC) analysis. A concen-
tration series was collected for each sample from 5 to 0.15 mg ml1. RawSimages were individually examined using PRIMUS (Konarev et al., 2003), and
images that showed radiation damage were excluded from the final aver-
aged curves. No concentration-dependent scattering was observed in for
PepT1ECD. Merged curves were created for PepT2ECD, as an increase in scat-
teringwas observed as a function of concentration in the low scattering angles.
To interpret the scattering data, 20 3Dmodels of each ECDwere created using
DAMMIF (Franke and Svergun, 2009), which were then aligned, clustered, and
averaged using DAMAVER (Volkov and Svergun, 2003). DAMMIN (Svergun,
1999) was then used to compare the averaged model against the raw data
to ensure a good fit as evaluated using reduced c2 values. Envelopes of the
models were generated using Sculptor (Birmanns et al., 2011).
Surface Plasmon Resonance
SPR experiments were carried out using a BIAcore T200 instrument (GE
Healthcare). Experiments were performed at 20C in 25 mM MES (pH 6.5),
100 mM NaCl, 10 mM CaCl2, 0.005% Tween 20, 2 mg ml
1 dextran, and
1 mg ml1 salmon sperm DNA (Sigma-Aldrich). Either PepT1ECD or PepT2ECD
were immobilized on a CM5 chip (GE Healthcare) by amine coupling (GE
Healthcare kit) to a total of 1,000 response units. A concentration series of
ligand (1000, 500, 250, 125, 62.5, 31.2, 15.6, and 7.81 mM) was injected over
the ECD-coated chip for 45 s at 90 ml min1, followed by a 30-s dissociation
time. The chip surface was then regenerated with 2 M NaCl for 30 s. Specific
binding of trypsin was obtained by subtracting the response from a blank sur-
face from that of the ECD-coated surface. The kinetic sensorgrams were fitted
to a global 1:1 interaction model, allowing determination of the dissociation
constant, KD, using BIAevaluation software 1.0 (GE Healthcare).
Microscale Thermophoresis
MST was carried out using a Monolith NT.115 instrument (NanoTemper).
Experiments were performed at 22C in 25 mM MES (pH 6.5) and 100 mM
NaCl. Both PepT1ECD and PepT2ECD were mutated to change a surface-
exposed serine to a cysteine (PepT1ECD-S437C and PepT2ECD-S427C) and
labeled with the blue maleimide labeling kit MO-L006 (NanoTemper). A range
of concentrations of the required ligand (range 0.03–1,000 mM) was incubated
with 1.5 mM of purified labeled protein. The sample was loaded into the Nano-
Temper glass capillaries and microthermophoresis was carried out using
100% LED power and 80% MST. KDs were calculated using the mass action
equation via the NanoTemper software from duplicate reads of triplicate
experiments.
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